Conor aims to enter market with bio-absorbable polymer stent

Calif.-based Conor Medsystems hopes to enter the $5 billion stent market next year with CoStar, a stent that begins as a drug-eluting product and then ceases drug production and absorbs the polymer coating after six months, leaving a bare metal stent, which should minimize the problem of late-thrombosis that is an issue in other drug-eluting stents. Conor still faces obstacles, such as the need for more data, not-so-deep pockets, potential court battles and marketing competition.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC